Synovial Sarcoma Clinical Trial
Official title:
Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases
The purpose of this study is to find out what effects, good and/or bad, radiation has on the lungs has on the patient and on synovial sarcoma which has spread to the lungs. The standard treatment for synovial sarcoma which has spread to the lungs is chemotherapy with or without surgery to remove the tumors in the lungs. However, tumors often come back in the lungs after chemotherapy and/or surgery. Since synovial sarcoma is known to be sensitive to radiation, this study is looking at whether radiation therapy which is targeted to the entire lung can further reduce the chances of the cancer returning. This type of radiation is commonly used in other types of sarcoma to treat the cancer once it has spread to the lungs and it may be very useful in synovial sarcoma as well. In this study, a special type of radiation will be used, called Intensity Modulated Radiation Therapy (IMRT). With IMRT the radiation beams are more customized to focus more radiation on the tumor cells while delivering less radiation to areas like the heart. The goal of this study is also to measure pulmonary toxicity and see if IMRT is feasible and has less toxicity.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Terminated |
NCT01957709 -
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
|
Early Phase 1 | |
| Not yet recruiting |
NCT06456359 -
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
|
Phase 2 | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
| Completed |
NCT03250325 -
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06094101 -
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03520959 -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
|
Phase 3 | |
| Terminated |
NCT02683148 -
DHEA in Synovial Sarcoma Patients
|
Phase 1 | |
| Recruiting |
NCT05642455 -
SPEARHEAD-3 Pediatric Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
| Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
| Terminated |
NCT04145700 -
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00004853 -
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
|
Phase 1 | |
| Suspended |
NCT06083883 -
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
|
Phase 1 | |
| Terminated |
NCT05355753 -
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 |